Black Diamond restructures to focus on BDTX-1535; CFO and CPO depart; cash runway extended to Q2 2026

Black Diamond Therapeutics, Inc.

CFO Fang Ni and CPO Elizabeth Montgomery depart; Erika Jones appointed Principal Financial Officer.
Restructuring: reduction in force, deprioritize BDTX-4933 to seek partners, outsource CMC activities.
Cash runway extended into Q2 2026 due to restructuring cost savings.
BDTX-1535 Phase 2 data in frontline and recurrent EGFRm NSCLC expected Q1 2025 with potential registration path.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Erika Jones

principal financial officer

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2024-10-07
Filed: October 7, 2024, 7:59 PM ET

Erika Jones, the Company’s Senior Vice President, Finance and Corporate Controller, and principal accounting officer, was appointed as principal financial officer of the Company.

Departed

Fang Ni

Chief Business Officer, Chief Financial Officer and principal financial officer

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2024-10-07
Successor: Erika Jones
Filed: October 7, 2024, 7:59 PM ET

On October 7, 2024, Black Diamond Therapeutics, Inc. (the “Company”) terminated Fang Ni, Pharm. D. without Cause (as such term is defined in his employment agreement with the Company, which was filed as Exhibit 10.12 to the Company’s Annual Report on Form 10-K filed on March 9, 2023 (the “Employment Agreement”)) as Chief Business Officer, Chief Financial Officer and principal financial officer of the Company, in each case, effective as of October 7, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Erika Jones was appointed as principal financial officer at Black Diamond Therapeutics, Inc..

Action: appointed
Role: principal financial officer

Exact text from the filing

Erika Jones, the Company’s Senior Vice President, Finance and Corporate Controller, and principal accounting officer, was appointed as principal financial officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Fang Ni was terminated as Chief Business Officer, Chief Financial Officer and principal financial officer at Black Diamond Therapeutics, Inc..

Action: terminated
Role: Chief Business Officer, Chief Financial Officer and principal financial officer

Exact text from the filing

On October 7, 2024, Black Diamond Therapeutics, Inc. (the “Company”) terminated Fang Ni, Pharm. D. without Cause (as such term is defined in his employment agreement with the Company, which was filed as Exhibit 10.12 to the Company’s Annual Report on Form 10-K filed on March 9, 2023 (the “Employment Agreement”)) as Chief Business Officer, Chief Financial Officer and principal financial officer of the Company, in each case, effective as of October 7, 2024

View on SEC.gov

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-106676

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.